Mark Christianson - Jun 23, 2021 Form 4/A - Amendment Insider Report for NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)

Role: Business Development Director
Signature: /s/ Stephanie Swan, by Power of Attorney
Stock symbol: NMTC
Transactions as of: Jun 23, 2021
Transactions value $: -$79,980
Form type: 4/A - Amendment
Date filed: 2/4/2022, 04:35 PM
Date Of Original Report: Jun 25, 2021
Next filing: Feb 4, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NMTC	Common Stock	Sale	-$76.2K	-11.3K	-3.11%	$6.74	352K	Jun 23, 2021	Direct	F1, F2
transaction	NMTC	Common Stock	Sale	-$3.78K	-600	-0.17%	$6.30	351K	Jun 24, 2021	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares of the issuer's common stock were sold in multiple transactions at prices ranging from $6.50 to $6.97, inclusive. The reporting person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range set forth in this footnote.
F2	This amendment is being filed to correct the number of shares beneficially owned by the reporting person following the reported transaction. The issuer effected a one-for-three reverse stock split of shares of its common stock on March 31, 2021, and the total number of shares held by the reporting person has been corrected to adjust for the split.

Content

The price reported in Column 4 is a weighted average price. These shares of the issuer's common stock were sold in multiple transactions at prices ranging from $6.50 to $6.97, inclusive. The reporting person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of common stock sold at each separate price within the range set forth in this footnote.

This amendment is being filed to correct the number of shares beneficially owned by the reporting person following the reported transaction. The issuer effected a one-for-three reverse stock split of shares of its common stock on March 31, 2021, and the total number of shares held by the reporting person has been corrected to adjust for the split.